中山痔疮发作时怎么办中山大便出血液,中山便血的疗法,中山肛门 瘙痒,中山大便时带血是什么症状,中山治疗痔疮费用,中山内痔医院咨询,中山怎么治疗肛裂

BAIKONUR, Kazakhstan, April 5 (Xinhua) -- Russia launched a spacecraft with three astronauts on board from the Kazakh Baikonur space center early on Tuesday, Xinhua correspondents reported from the site.The Soyuz TMA-21 spacecraft atop a Soyuz-FG carrier rocket blasted off at 02:18 a.m. Moscow time (2218 GMT April 4), sending to the International Space Station (ISS) Russian cosmonauts Alexander Samokutyaev and Andrei Borisenko and U.S. astronaut Ronald Garn.The Russian Soyuz TMA-21 spacecraft, named after the first cosmonaut Yuri Gagarin, carrying the International Space Station (ISS) crew of U.S. astronaut Ronald Garan, Russian cosmonauts Alexandr Samokutyaev and Andrey Borisenko, blasts off at the Baikonur cosmodrome, April 5, 2011.The Soyuz TMA-21, named after the first cosmonaut Yuri Gagarin, was scheduled to dock with the ISS at 03:18 a.m. Moscow time (2318 GMT April 6) on Thursday.According to the Russian Federal Space Agency (Roscosmos), the three new crew members are expected to spend 170 days in the ISS. During the period, they will receive two U.S. space shuttles and three Russian Progress cargo ships, conduct a spacewalk and carry out over 40 experiments.The launch is dedicated to the 50th anniversary of the first flight into space in 1961 carried out by Gagarin.

BEIJING, March 15 (Xinhuanet) -- The number of Alzheimer patients is growing rapidly, so is that of unpaid caregivers, says a report released Tuesday by the Alzheimer's Association.Nearly 15 million caregivers, most of them family members but also friends, are providing billions of hours of unpaid care for Alzheimer's patients and other forms of dementia in the U.S. — 37 percent more than last year, the report says.Alzheimer's is the sixth leading cause of death in the nation, and the only one among the top 10 that have no prevention or cure, says William Thies, chief medical and scientific officer of the Alzheimer's Association.However, if people were more aware of early symptoms and were diagnosed sooner, then planning could help ease stress on patients and caregivers, according to Beth Kallmyer, senior director of constituent services of Alzheimer's Association."The toll on families is devastating," says Kallmyer, "Stress is extremely high, and one-third are experiencing depression."The time and stress of caring for an Alzheimer’s patient takes a physical toll, translating into nearly 8 billion dollars worth of extra health care costs for caregivers, the report says.

NAIROBI, Jan. 28 (Xinhua) -- Although exact details surrounding the situation are not known at this time, there are indications that the fishing vessel TAI JUAN 227 from China's Taiwan has been released from pirate control, the EU anti piracy mission said on Friday.The vessel, which had a crew of 28 at the time of the attack, was pirated on May 6, 2010 while operating 700 Nm North East of Seychelles.EU Naval Force spokesman Paddy O'Kennedy said in a statement that although direct contact with the crew has not been possible, the vessel's owners apparently received a call from the master stating that they had been released but that they did not know why.According to the EU naval force, the crew were provided with fresh food and water by a U.S. warship after the release. The vessel is currently heading away from Somalia.The naval spokesman also said that there is confusion surrounding the details of the release as, until three days ago, the FV TAI YUAN 227 was suspected as being used as a pirate mothership.The Gulf of Aden, a body of water between Somalia and Yemen, is the main sea route between Europe and Asia.Tankers carrying Middle East oil through the Suez Canal must pass first through the Gulf of Aden. Pirate gangs operating along Somalia's coastline have become increasingly audacious over the past two years, hijacking dozens of merchant ships and their crews to earn ransoms that can top 1 million U.S. dollars per ship.So far the fledgling Somali government has not dared go after the pirate strongholds, since pirate leaders have more power than the beleaguered government.

CHENGDU, May 8 (Xinhua) -- As a brand-name herbal capsule for cardiovascular disease in China, Di'ao Xinxuekang only needs to wait for another 15 years before reaching the EU market."The Dutch medical supervisors have recognized it as a qualified drug, but we still lack the evidence of 15-year presence in the EU market," said Ji Jianxin, a research manager with the drug's developer Di'ao Group based in southwest China's Sichuan Province.Di'ao, one of the largest Traditional Chinese Medicine (TCM) manufacturers, has been quite depressed, as many other TCM enterprises in China, by a European Union directive on traditional herbal medicinal products fully implemented from the beginning of this month.The directive requires that all herbal medicinal products, must obtain a medical license from any EU member state before it can be allowed in the EU market.It introduced a so-called simplified registration procedure with a seven-year transition period for traditional herbal medicinal products to be licensed, including Chinese and Indian ones.However, not a single Chinese herbal medicinal product has been granted the license so far, mainly due to the prohibitive registration cost and lack of required evidence to prove the product had a 30-year history of safe use, including 15 years in the EU.With a history of more than 2,000 years, TCM did not enter into the EU market until mid-1990s, and it has been imported into the EU and sold to European customers as food supplements instead of drugs.Most Chinese producers and importers did not reserve the customs papers a decade ago, thus unable to prove the 15-year use of their products in European markets.While TCM's globalization won't be doomed by one single EU directive as TCM export value to EU only takes up 14 percent of the total in 2010, experts and industry insiders still have had serious concerns about its future."Most TCM even don't have standardized labels that can help consumers to find out its origin," said Xian Sheng, from the China Association of TCM Export Companies.

WASHINGTON, April 6 (Xinhua) -- A study led by researchers at the University of Michigan (U-M) showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells. The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppresser function. This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53."For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer," says lead study author Shaomeng Wang, director of the Cancer Drug Discovery Program at the U-M Comprehensive Cancer Center.Wang presented the study Wednesday at the American Association for Cancer Research 102nd annual meeting.Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects. These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study, which was done in collaboration with Ascenta Therapeutics and Sanonfi-Aventis, researchers showed that these new drugs shrank tumors without significant side effects.Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer. Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.